[{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2\/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III"}]
Find Clinical Drug Pipeline Developments & Deals for Inaxaplin
VX-147 (inaxaplin) is an oral, small-molecule inhibitor of APOL1 channel function, which is being evaluated for the treatment of APOL1-mediated kidney disease.
(VX-147) inaxaplin is an orally active APOL1 inhibitor aimed at treating the underlying cause of focal segmental glomerulosclerosis (FSGS) and APOL1-mediated kidney disease (AMKD).
The primary efficacy endpoint for the final analysis is eGFR slope in patients receiving the VX-147 (inaxaplin) selected dose compared to placebo. The secondary efficacy endpoint is time to composite clinical outcome.